AC-201
Moderate-to-Severe Plaque Psoriasis
Phase 2Completed (China); partnered with Fosun Pharma for Greater China
Key Facts
Indication
Moderate-to-Severe Plaque Psoriasis
Phase
Phase 2
Status
Completed (China); partnered with Fosun Pharma for Greater China
Company
About Accro Bioscience
Clinical-stage biotech developing novel therapeutics targeting regulated cell death mechanisms for immune-mediated diseases and cancer.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| ICOTYDE (icotrokinra) | Johnson and Johnson Innovative Medicine | Approved |
| TAK-279 (NDI-034858) | Takeda | Phase 3 |
| ILUMYA® (tildrakizumab-asmn) | Sun Pharmaceutical | Commercial |
| Iruxolimab (AK101) | Akeso | Approved |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Approved |
| Envudeucitinib (ESK-001) | Alumis | Phase 3 |
| ORKA-001 | Oruka Therapeutics | Phase 1/2 |